期刊
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
卷 66, 期 2, 页码 184-192出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2015.05.030
关键词
adherence; ezetimibe; low-density lipoprotein cholesterol; secondary prevention; statin therapy
资金
- Amgen
- AstraZeneca
- Sanofi
- Aegerion
- Eli Lilly
- Genzyme
- GlaxoSmithKline
- Novartis
- Regeneron
In addition to aggressive lifestyle and nonlipid risk factor modification, statin therapy improves cardiovascular disease outcomes following acute coronary syndromes. Despite established benefits of treatment, contemporary registries reveal substantial underutilization of and nonadherence to statin therapy for secondary prevention. In randomized controlled trials investigating statin therapy, including moderate-intensity statin plus ezetimibe therapy, rates of nonadherence are reported in up to 40% of subjects. Durable strategies to address gaps in lipid lowering for secondary prevention are essential to maximize reduction in cardiovascular disease risk. (C) 2015 by the American College of Cardiology Foundation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据